Status:
COMPLETED
Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease
Lead Sponsor:
Bayside Health
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
40-85 years
Phase:
PHASE4
Brief Summary
Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our preliminary findings indicate that the drug ramipril is much more effective in improving walking ability t...
Detailed Description
This proposal extends our novel finding that the angiotensin-converting enzyme (ACE) inhibitor, ramipril markedly improves walking ability in patients with peripheral arterial disease (PAD), by conduc...
Eligibility Criteria
Inclusion
- Ankle brachial index of \<0.9 in at least one leg
- History of intermittent claudication (unilateral or bilateral)
- A stable medication regimen for at least 6 months
Exclusion
- Limiting coronary artery disease
- Renal failure (serum creatinine \> 0.20 mmol/L)
- Current treatment or treatment within the previous 6 months with ACE inhibitors or angiotensin II receptor antagonists
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00681226
Start Date
January 1 2008
End Date
January 1 2012
Last Update
April 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baker Heart Research Institute
Melbourne, Victoria, Australia, 8008